AU2010310515B2 - Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment - Google Patents

Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment Download PDF

Info

Publication number
AU2010310515B2
AU2010310515B2 AU2010310515A AU2010310515A AU2010310515B2 AU 2010310515 B2 AU2010310515 B2 AU 2010310515B2 AU 2010310515 A AU2010310515 A AU 2010310515A AU 2010310515 A AU2010310515 A AU 2010310515A AU 2010310515 B2 AU2010310515 B2 AU 2010310515B2
Authority
AU
Australia
Prior art keywords
patient
diet
cancer
chemotherapy
predetermined period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010310515A
Other languages
English (en)
Other versions
AU2010310515A1 (en
Inventor
Changhan Lee
Valter D. Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2010310515A1 publication Critical patent/AU2010310515A1/en
Application granted granted Critical
Publication of AU2010310515B2 publication Critical patent/AU2010310515B2/en
Priority to AU2016201607A priority Critical patent/AU2016201607B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Business, Economics & Management (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Economics (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Marketing (AREA)
  • Theoretical Computer Science (AREA)
  • Human Resources & Organizations (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Operations Research (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010310515A 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment Active AU2010310515B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016201607A AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
US61/254,154 2009-10-22
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016201607A Division AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (2)

Publication Number Publication Date
AU2010310515A1 AU2010310515A1 (en) 2012-05-17
AU2010310515B2 true AU2010310515B2 (en) 2016-01-07

Family

ID=43900993

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2010310515A Active AU2010310515B2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
AU2016201607A Active AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016201607A Active AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Country Status (13)

Country Link
US (2) US20110118528A1 (https=)
EP (1) EP2490684B1 (https=)
JP (1) JP2013508411A (https=)
CN (1) CN102753162A (https=)
AU (2) AU2010310515B2 (https=)
BR (1) BR112012009423A2 (https=)
CA (1) CA2779282C (https=)
DK (1) DK2490684T3 (https=)
ES (1) ES2659353T3 (https=)
PL (1) PL2490684T3 (https=)
PT (1) PT2490684T (https=)
RU (1) RU2549954C2 (https=)
WO (1) WO2011050302A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888811C (en) * 2012-10-22 2023-10-24 University Of Southern California A diet package, and uses thereof
CN109187991B (zh) 2013-02-12 2021-12-24 南加利福尼亚大学 为受试者提供合理蛋白质膳食的方法
WO2015002972A1 (en) * 2013-07-01 2015-01-08 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
JP6859567B2 (ja) * 2014-03-06 2021-04-14 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
US10117872B2 (en) * 2014-03-28 2018-11-06 Università Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
CA2944479C (en) * 2014-04-02 2023-02-21 University Of Southern California Dietary formulation and method for treating autoimmune and inflammatory diseases
AU2016248443B2 (en) * 2015-04-16 2021-03-18 University Of Southern California Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
RU2724525C2 (ru) 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
EP3352793A1 (en) * 2015-09-21 2018-08-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare New therapeutic strategies against blood cancer
EP3402345A4 (en) * 2016-01-12 2019-09-11 University of Southern California USE OF LONG-TERM FAST FOR IMMEDIATE DIETARY TREATMENT OF MULTIPLE MYELOMA AND OTHER CANCER TYPES
JP2019505592A (ja) 2016-02-15 2019-02-28 ユニバーシティ オブ サザン カリフォルニア 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法
CN109069462A (zh) 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
US11540550B2 (en) 2016-05-11 2023-01-03 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
EP3765046A4 (en) 2018-03-15 2022-04-27 University Of Southern California BUT NOT EXCLUSIVELY WATER-BASED DIET (FMD) FACILITATES THE REVERSAL OF INFLAMMATION AND INFLAMMATORY BOWEL DISEASE
US20210267250A1 (en) * 2018-07-18 2021-09-02 Andreas Michalsen Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
MX2021005465A (es) 2018-11-09 2021-12-15 L Nutra Barra nutricional para simular el ayuno intermitente.
WO2020223522A1 (en) 2019-04-30 2020-11-05 University Of Southern California Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP7376718B2 (ja) * 2019-12-13 2023-11-08 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CA3205396A1 (en) * 2020-12-17 2022-06-23 Licia Rivoltini Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823B1 (en) 2021-03-30 2025-04-30 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Reduced caloric intake and anticancer agents for the treatment of cancer
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学（Cn） 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
EP4599826A1 (en) 2024-02-06 2025-08-13 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Leucine for use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070378A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
CA2283642C (en) * 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
AU5319499A (en) * 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
EP2156188B1 (en) * 2007-03-28 2021-05-05 University of Southern California Induction of differential stress resistance and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070378A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BYERS T, et al. CA A Cancer Journal for Clinicians, (2002) Vol 52 pp 92-119 *
FOLADOR A, et al. Int J Cancer, (2006) Vol 120, pp 344-350. *
KLURFELD et al. Cancer Research, (1987) Vol 47, pp 2759-2762. *
MIZUSHIMA N, et al. Nature, (2008) Vol 451(7182) pp 1069-1075. *
RAFFAGHELLO L, et al. PNAS, (2008) Vol 105 No 24 pp 8215-8220. *

Also Published As

Publication number Publication date
PT2490684T (pt) 2018-04-02
DK2490684T3 (en) 2018-04-09
US20110118528A1 (en) 2011-05-19
EP2490684B1 (en) 2018-01-03
US20210209516A1 (en) 2021-07-08
EP2490684A4 (en) 2016-05-04
RU2012118588A (ru) 2013-11-27
JP2013508411A (ja) 2013-03-07
CA2779282A1 (en) 2011-04-28
CA2779282C (en) 2017-12-05
WO2011050302A2 (en) 2011-04-28
WO2011050302A3 (en) 2011-08-25
PL2490684T3 (pl) 2018-07-31
AU2016201607A1 (en) 2016-03-31
AU2010310515A1 (en) 2012-05-17
CN102753162A (zh) 2012-10-24
EP2490684A2 (en) 2012-08-29
AU2016201607B2 (en) 2017-11-30
RU2549954C2 (ru) 2015-05-10
BR112012009423A2 (pt) 2017-06-13
ES2659353T3 (es) 2018-03-14

Similar Documents

Publication Publication Date Title
US20210209516A1 (en) Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
JP7038432B2 (ja) 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
Miyata et al. Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer
RU2734774C2 (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
JP2021101721A (ja) 癌における食事療法の開発
US12036246B2 (en) Compositions and methods for enhancing cancer chemotherapy
US20150250771A1 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
WO2018170457A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Cipolla et al. Treating metastatic castration-resistant prostate cancer with novel polyamine-free oral nutritional supplementation: Phase I study
JP2023551730A (ja) 断食模倣食は、急性リンパ芽球性白血病モデルにおける無がん生存を促進する
HK1233488B (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
Cipolla et al. Effect of combination of a polyamine-free oral nutritional supplement and docetaxel in symptomatic, metastatic castration-resistant prostate cancer patients
Tan Why Do Cancer Patients Take More Vitamins?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)